ArticleEcancermedicalscience2024
Utility of glass slide morphology (GSM) and whole slide image (WSI) in the diagnosis of acute leukemia (AL) by types.
Article in Ecancermedicalscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute leukemia (AL) is a diverse group of hematological malignancies characterised by the accumulation of immature blast cells in the bone marrow. Accurate classification into acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) is essential for treatment and prognosis. This study aimed to assess the performance of glass slide morphology (GSM) using a light microscope versus whole slide imaging (WSI) in diagnosing and classifying AL, using flow cytometry as the gold standard test. Peripheral smears and bone marrow aspirates from 97 patients suspected of AL were stained with Romanowsky stain and reviewed by a single hematologist. For GSM, the hematologist was provided with a single slide, which was to be evaluated under a light microscope. For WSI, the Alexapath mobile scanner (ADA1) was used to scan the slides for review by the hematologist. Patient identification was concealed from the interpreting hematologist, and an interval of 2 weeks was set between the review of GSM and WSI of the same patient. The sensitivity and specificity of GSM and WSI were compared to the results of flow cytometry. Out of the 97 patients suspected to have AL, 47 were confirmed to have AL by flow cytometry. Among these, 19 (40.4%) were diagnosed with AML and 28 (59.6%) with ALL. GSM demonstrated high sensitivity (89.4%) and specificity (90.0%) for diagnosing AL, but lower sensitivity in distinguishing AML (57.9%) from ALL (75.0%). Similarly, WSI exhibited a reasonable sensitivity (80.9%) and high specificity (98.0%) for diagnosing AL, but lower sensitivity in differentiating AML (57.9%) and ALL (46.4%). GSM and WSI are reasonable and acceptable techniques for accurately screening AL cases and accelerating referral to tertiary centers of excellence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.